

Applicant : Cy A. Stein et al.  
Serial No.: 09/832,648  
Filed : April 11, 2001  
Page 5

- 60. (New) The method of claim 59, further comprising administering chemotherapy to the patient.--
- 61. (New) The pharmaceutical composition of claim 58, further comprising a colloidal dispersion system.--
- C! --62. (New) An antisense compound at least 10 nucleotides in length targeted to a nucleic acid molecule encoding a human bcl-x, wherein said antisense compound modulates the expression of human bcl-x, and wherein said antisense compound is an antisense oligonucleotide which comprises at least a 10 nucleobase portion of sequence C,D,E,F,G,I and M of Figure 1.--
- 

REMARKS

Claims 9, 26-30 and 32 to 36 are pending in this application in view of the Preliminary Amendment filed April 11, 2001. By this Supplemental Preliminary Amendment new claims 37-62 are being added. New claims 37 and 38 recite subject matter overlapping with claim 1 of U.S. Patent No. 6,172,216 issued January 9, 2001 ("216 patent"). Sequence B (SEQ ID NO:2) of these claims 37 and 38 is identical to SEQ ID NO:21 of claim 1 of the '216 patent. New claim 62 is similar to new claim 37, but adds 7 additional sequences, C,D,E,F,G,I and M which correspond substantially to SEQ ID NO.s: 37, 32, 22, 26, 3, 23 and 6 respectively of claim 1 of the '216 patent. Some of the other claims being added herein overlap with other claims of the '216 patent. After entry of this Supplemental Preliminary Amendment claims 9, 26-30, 32-62 will be pending.

Applicants maintain that the amendments to the claims raise no issue of new matter and that the amended claim is fully supported

Applicant : Cy A. Stein et al.  
Serial No.: 09/832,648  
Filed : April 11, 2001  
Page 6

by the specification as originally filed. Applicants, therefore, respectfully request entry of these amendments. Support for new claim 37 can be found, *inter alia*, in the specification as originally filed at page 1, line 39 to page 2 line 2; page 3, lines 2-5; page 20, lines 3-8 and page 20, lines 31 to 34 and Figure 1. Support for new claim 38 can be found, *inter alia*, in the specification as originally filed at page 1, line 39 to page 2 line 2; page 3, lines 2-5; page 20, lines 3-8 and page 20, lines 31 to 34 and Figure 1. Support for new claim 39 can be found in the specification as originally filed at page 13, lines 27-30. Support for new claim 40 can be found in the specification as originally filed at page 13, lines 32-35. Support for new claim 41 can be found in the specification as originally filed at page 13, line 37 to page 14, line 3. Support for new claim 42 can be found in the specification as originally filed at page 14, lines 5-8. Support for new claim 43 can be found in the specification as originally filed at page 14, line 10-13. Support for new claim 44 can be found in the specification as originally filed at page 6, line 36 to page 7 line 9. Support for new claim 45 can be found in the specification as originally filed at page 7, lines 14-16. Support for new claim 46 can be found in the specification as originally filed at page 7, lines 27-31. Support for new claim 47 can be found in the specification as originally filed at page 8, lines 36-37. Support for new claim 48 can be found in the specification as originally filed at page 10, lines 5-6. Support for new claim 49 can be found in the specification as originally filed at page 10, line 32. Support for new claim 50 can be found in the specification as originally filed at page 10, lines 5-6. Support for new claim 51 can be found in the specification as originally filed at page 14, lines 20-24. Support for new claim 52 can be found in the specification as originally filed at page 13, lines 22-25. Support

Applicant : Cy A. Stein et al.  
Serial No.: 09/832,648  
Filed : April 11, 2001  
Page 7


for new claim 53 can be found in the specification as originally filed at page 8, lines 36-37. Support for new claim 54 can be found in the specification as originally filed at page 8, lines 36-37. Support for new claim 55 can be found, *inter alia*, in the specification as originally filed at page 20, lines 31-34. Support for new claim 56 can be found in the specification as originally filed at page 16, lines 15-19. Support for new claim 57 can be found in the specification as originally filed at page 24, lines 23-26. Support for new claim 58 can be found in the specification as originally filed at page 18, lines 24-28. Support for new claim 59 can be found in the specification as originally filed at page 16, lines 15-21. Support for new claim 60 can be found in the specification as originally filed at page 24, lines 23-26. Support for new claim 61 can be found in the specification as originally filed at page 11, lines 19 and 34, page 25, lines 8-11. Support for new claim 62 can be found, *inter alia*, in the specification as originally filed at page 1, line 39 to page 2 line 2; page 3, lines 2-5; page 20, lines 3-8 and page 20, lines 31 to 34 and Figure 1.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invite the Examiner to telephone him at the number provided below.

Applicant : Cy A. Stein et al.  
Serial No.: 09/832,648  
Filed : April 11, 2001  
Page 8


A fee of \$848.00 is deemed necessary in connection with the filing of this Supplemental Preliminary Amendment. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231.

 1/9/02  
Peter J. Phillips Date  
Registration No. 29,691

John P. White  
Registration No. 28,678  
Peter J. Phillips  
Registration No. 29,691  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400